Efficacy of add-on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double-blind, placebo-controlled trial with an open-label extension phase
ISRCTN | ISRCTN00721331 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN00721331 |
Secondary identifying numbers | 7183 |
- Submission date
- 19/09/2005
- Registration date
- 25/05/2006
- Last edited
- 20/11/2012
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Grigori Joffe
Scientific
Scientific
Hospital of Kellokoski
Kellokoski
04500
Finland
Phone | +358 (0)40 5136500 |
---|---|
grigori.joffe@kolumbus.fi |
Study information
Study design | Double-blind, placebo-controlled trial with an open-label extension phase |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Scientific title | |
Study objectives | Mirtazapine will improve negative, possibly positive and extrapyramidal symptoms, as well as neurocognition, if added to a conventional antipsychotic. |
Ethics approval(s) | Approved by the Republican Commision on Medical Ethics, Petrozavodsk (Session #6, Sept 9, 2004) |
Health condition(s) or problem(s) studied | Schizophrenia |
Intervention | Add-on mirtazapine versus placebo. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Mirtazapine |
Primary outcome measure | Positive and negative syndrome scale (PANSS) total scores. |
Secondary outcome measures | 1. Number of responders (20% or more decline on PANSS total or subscores) 2. Change in standard neurocognitive tests |
Overall study start date | 10/10/2004 |
Completion date | 31/12/2006 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Upper age limit | 65 Years |
Sex | Both |
Target number of participants | 40 |
Key inclusion criteria | Male or female in- or out-patients will be recruited if: 1. They are aged 18-65 years 2. Have schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) (APA, 1994); defined schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated) or schizo-affective disorder, depressive type 3. Receiving one or more conventional antipsychotics at cumulative daily dose of at least 400 mg chlorpromazine equivalents (e.g. haloperidol 12 mg daily) (see Table of Antipsychotic Equivalents), which has remained unchanged (also in terms of dosage) during at least 6 last weeks prior to screening baseline (8 weeks for depot antipsychotics). Table of antipsychotic equivalents (Basire, 2000) oral mg/day: chlorpromazine 100 mg (= 25-50 mg intramuscular (IM) or 250 mg rectal), fluphenazine 2 mg, levomeptromazine - not known, pericyazine 24 mg, perphenazine 8 mg, prochlorperazine 15 mg, promazine 100 mg, thioridazine 100 mg, trifluoperazine 5 mg, benperidol 2 mg, droperidol 4 mg (Short t1/2) or 3 mg IM/intravenous (IV), haloperidol 3 mg or 1.5 mg IM/IV for doses up to 150 mg/day, trifluoperidol 2 mg, flupentixol 2 mg, zuclopentixol 25 mg up to 150 mg/day, pimozide 2 mg (Long t1/2), remoxiprid 75 mg, amisulpride 100 mg, sulpiride 200 mg, loxapine 10 mg depot (mg/week), fluphenazine 5-10 mg (1-12.5 mg), pipothiazine 10 mg (5-12.5 mg), haloperidol 15 mg (5-12.5 mg), flupentixol 10 mg (8-20 mg), zuclopentixol 100 mg (40-100 mg), fluspirilene 2 mg - not fully established. 4. Demonstrating less than optimal clinical outcome i.e. experiencing either positive or negative symptoms (disability due to only general symptoms will be insufficient for inclusion) resulting in the illness of at least moderate severity (i.e. 4, moderately ill, or more on the clinical global impression (CGI), severity item) (Guy, 1970) 5. The clinical condition has remained stable during the last 6 weeks prior to the baseline visit 6. The patient has a level of understanding that enables reasonable cooperation with the investigator and the ability to fulfil the neurocognitive tests 7. The patient has given written informed consent |
Key exclusion criteria | 1. History of allergy or serious adverse events due to mirtazapine 2. Previous lack of response to a trial with mirtazapine in daily doses of 30 mg or more during four or more weeks, added to the patients current or earlier conventional antipsychotic medication 3. Previous lack of response to another antidepressant with affinity to postsynaptic (5-hydroxytryptamine) 5HT2 receptors (e.g. mianserine, trazodone, or nefazodone) used in adequate doses during four or more weeks 4. Current atypical antipsychotic medication (e.g. clozapine, risperidone, olanzapine, sertindole, quetiapine, zotepine, ziprasidone, etc.) 5. History of non-response to either clozapine or other atypical antipsychotics 6. Medical or neurological condition or drug treatment that might put patients at serious risk or bias the assessment of their clinical or mental status (e.g. serious unstable physical illness, epilepsy, organic brain syndrome etc.) 7. History of or current bipolar disorder or schizoaffective disorder, bipolar type (patients with schizoaffective disorder, depressive type can participate in the study) 8. Substance addiction or abuse within the last three months prior to screening 9. Clearly predictable poor compliance 10. For females of child-bearing potential: pregnancy, lactation, or inability or unwillingness to use medically acceptable methods of contraception during the study 11. Treatment with any antidepressant, mood stabilizer, regular (i.e. four or more times within 1 week) use of sumatriptan, naratriptan, zolmitriptan, or drugs with similar mechanism of action, or buspiron or drugs with similar mechanism of action - within four weeks (for fluoxetine, six weeks) prior to baseline. Accidental use of the drugs for treatment of migraine listed above is forbidden on the day of clinical assessment before the assessment. 12. Treatment with antipsychotics other than those currently in use within six weeks prior to baseline 13. Treatment with benzodiazepines as follows: a. Regular use (i.e. four or more times weekly) of any benzodiazepines at any doses during any of the last four weeks prior to baseline, if they have being received for less than two months. However, regular use of benzodiazepines is permitted if they are absolutely necessary and have been received during two or more months prior to baseline in stable daily doses not exceeding 30 mg of diazepam or comparable doses of other benzodiazepines, as determined by the table of equivalents (Bazire, 2000). b. Accidental use (i.e. three or less times weekly) of benzodiazepines in daily doses exceeding 30 mg of diazepam or comparable doses of other benzodiazepines (see table of equivalents) (i.e. accidental use of 30 mg or less of diazepam or comparable doses of other benzodiazepines is not a criterion for exclusion). Use of benzodiazepines on the day of clinical assessment is forbidden before the assessment. 14. Electroconvulsive therapy (ECT) within three months prior to baseline 15. Any clinically relevant abnormality detected during the physical examination or laboratory screening tests and likely to interfere with the conduct of the study |
Date of first enrolment | 10/10/2004 |
Date of final enrolment | 31/12/2006 |
Locations
Countries of recruitment
- Finland
Study participating centre
Hospital of Kellokoski
Kellokoski
04500
Finland
04500
Finland
Sponsor information
Stanley Medical Research Institute (USA)
Research organisation
Research organisation
5430 Grosvenor Lane
Suite 200
Bethesda
MD 20814-2142
United States of America
Phone | +1 301 571 0760 ext 124 |
---|---|
herrerax@stanleyresearch.org | |
Website | http://www.stanleyresearch.org |
https://ror.org/01pj5nn22 |
Funders
Funder type
Research organisation
Stanley Medical Research Institute
Private sector organisation / Research institutes and centers
Private sector organisation / Research institutes and centers
- Alternative name(s)
- The Stanley Medical Research Institute, SMRI
- Location
- United States of America
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/01/2013 | Yes | No |